Likuiditas cepet Ikena Oncology, Inc. (IKNA)

The share price history of Ikena Oncology, Inc. (IKNA) reflects the dynamics of an asset whose operations rely on developing drugs for targeted impact on rare genetic tumor mutations. The indicator stands at 14.11. While the business previously developed AI-driven biomarker discovery and cell death mechanisms, the company has now shifted to a strict austerity mode, reducing headcount and focusing on testing a single lead candidate.

For Ikena Oncology, Inc. (IKNA), which develops precision targeted tumor therapies, the quick ratio serves as an indicator of financial viability. This metric determines the company's ability to settle short-term obligations without liquidating illiquid assets. The calculation is based on the ratio of cash and accounts receivable to current liabilities. High values confirm capital stability, although an excess of non-working assets may limit the overall profitability of the business.